References
- Higgins RD. Oxygen saturation and retinopathy of prematurity. Clin Perinatol. 2019;46(3):593–599. doi:10.1016/j.clp.2019.05.008.
- Jobe AH. Mechanisms of lung injury and bronchopulmonary dysplasia. Am J Perinatol. 2016;33(11):1076–1078.
- Wang J, Dong W. Oxidative stress and bronchopulmonary dysplasia. Gene. 2018;678:177–183. doi:10.1016/j.gene.2018.08.031.
- Zhu X, Lei X, Wang J, et al. Protective effects of resveratrol on hyperoxia-induced lung injury in neonatal rats by alleviating apoptosis and ROS production. J Matern Fetal Neonatal Med. 2020;33(24):4150–4158.
- Hui W, Dai Y. Therapeutic potential of aryl hydrocarbon receptor ligands derived from natural products in rheumatoid arthritis. Basic Clin Pharmacol Toxicol. 2020;126(6):469–474. doi:10.1111/bcpt.13372.
- Beránek M, Fiala Z, Kremláček J, et al. Serum levels of aryl hydrocarbon receptor, cytochromes P450 1A1 and 1B1 in patients with exacerbated psoriasis vulgaris. Folia Biol (Praha). 2018;64(3):97–102.
- Miyajima A, Kuroda Y, Sakemi-Hoshikawa K, et al. Inhibitory and inductive effects of 4- or 5-methyl-2-mercaptobenzimidazole, thyrotoxic and hepatotoxic rubber antioxidants, on several forms of cytochrome P450 in primary cultured rat and human hepatocytes. Toxicol Rep. 2020; 7:979–985. doi:10.1016/j.toxrep.2020.08.003.
- Wang K, Lv Q, Miao YM, et al. Cardamonin, a natural flavone, alleviates inflammatory bowel disease by the inhibition of NLRP3 inflammasome activation via an AhR/Nrf2/NQO1 pathway. Biochem Pharmacol. 2018;155:494–509. doi:10.1016/j.bcp.2018.07.039.
- Fujii-Kuriyama Y, Kawajiri K. Molecular mechanisms of the physiological functions of the aryl hydrocarbon (dioxin) receptor, a multifunctional regulator that senses and responds to environmental stimuli. Proc Jpn Acad Ser B Phys Biol Sci. 2010;86(1):40–53. doi:10.2183/pjab.86.40.
- Thatcher TH, Maggirwar SB, Baglole CJ, et al. Aryl hydrocarbon receptor-deficient mice develop heightened inflammatory responses to cigarette smoke and endotoxin associated with rapid loss of the nuclear factor-kappaB component RelB. Am J Pathol. 2007;170(3):855–864. doi:10.2353/ajpath.2007.060391.
- Quintana FJ, Sherr DH. Aryl hydrocarbon receptor control of adaptive immunity. Pharmacol Rev. 2013;65(4):1148–1161. doi:10.1124/pr.113.007823.
- Rahman Z, Dwivedi DK, Jena GB. Ethanol-induced gastric ulcer in rats and intervention of tert-butylhydroquinone: involvement of Nrf2/HO-1 signalling pathway. Hum Exp Toxicol. 2020;39(4):547–562. doi:10.1177/0960327119895559.
- Zhu J, Luo L, Tian L, et al. Aryl hydrocarbon receptor promotes IL-10 expression in inflammatory macrophages through Src-STAT3 signaling pathway. Front Immunol. 2018;9:2033. doi:10.3389/fimmu.2018.02033.
- Patil AS, Singh AD, Mahajan UB, et al. Protective effect of omeprazole and lansoprazole on β-receptor stimulated myocardial infarction in wistar rats. Mol Cell Biochem. 2019;456(1-2):105–113. doi:10.1007/s11010-019-03494-y.
- Badr AM, El-Orabi NF, Ali RA. The implication of the crosstalk of Nrf2 with NOXs, and HMGB1 in ethanol-induced gastric ulcer: potential protective effect is afforded by raspberry ketone. PLoS One. 2019;14(8):e0220548. doi:10.1371/journal.pone.0220548.
- Hashioka S, Klegeris A, McGeer PL. Proton pump inhibitors reduce interferon-γ-induced neurotoxicity and STAT3 phosphorylation of human astrocytes. Glia. 2011;59(5):833–840. doi:10.1002/glia.21157.
- Shivanna B, Chu C, Welty SE, et al. Omeprazole attenuates hyperoxic injury in H441 cells via the aryl hydrocarbon receptor. Free Radic Biol Med. 2011;51(10):1910–1917. doi:10.1016/j.freeradbiomed.2011.08.013.
- Yang X, Dong WB, Lei XP, et al. Resveratrol suppresses hyperoxia-induced nucleocytoplasmic shuttling of SIRT1 and ROS production in PBMC from preterm infants in vitro. J Matern Fetal Neonatal Med. 2018;31(9):1142–1150.
- Hansmann G, Sallmon H, Roehr CC, European Pediatric Pulmonary Vascular Disease Network (EPPVDN)., et al. Pulmonary hypertension in bronchopulmonary dysplasia. Pediatr Res. 2021;89(3):446–455. doi:10.1038/s41390-020-0993-4.
- Rakshasbhuvankar AA, Simmer K, Patole SK, et al. Enteral vitamin a for reducing severity of bronchopulmonary dysplasia: a randomized trial. Pediatrics. 2021;147(1):e2020009985. doi:10.1542/peds.2020-009985.
- Filippone M, Nardo D, Bonadies L, et al. Update on postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Am J Perinatol. 2019;36(S 02):S58–S62. Epub 2019 Jun 25. doi:10.1055/s-0039-1691802.
- Ofman G, Caballero MT, Alvarez Paggi D, et al. The discovery BPD (D-BPD) program: study protocol of a prospective translational multicenter collaborative study to investigate determinants of chronic lung disease in very low birth weight infants. BMC Pediatr. 2019;19(1):227. doi:10.1186/s12887-019-1610-8.
- Day CL, Ryan RM. Bronchopulmonary dysplasia: new becomes old again!. Pediatr Res. 2017;81(1-2):210–213. doi:10.1038/pr.2016.201.
- Sahni M, Mowes AK. Bronchopulmonary dysplasia. Treasure Island (FL): StatPearls Publishing; 2021.
- Savani RC. Modulators of inflammation in bronchopulmonary dysplasia. Semin Perinatol. 2018;42(7):459–470. doi:10.1053/j.semperi.2018.09.009.
- Papagianis PC, Pillow JJ, Moss TJ. Bronchopulmonary dysplasia: pathophysiology and potential anti-inflammatory therapies. Paediatr Respir Rev. 2019;30:34–41. doi:10.1016/j.prrv.2018.07.007.
- Yeh TF, Chen CM, Wu SY, et al. Intratracheal administration of budesonide/surfactant to prevent bronchopulmonary dysplasia. Am J Respir Crit Care Med. 2016;193(1):86–95. doi:10.1164/rccm.201505-0861OC.
- Zhao W, Ma L, Cai C, et al. Caffeine inhibits NLRP3 inflammasome activation by suppressing MAPK/NF-κB and A2aR signaling in LPS-Induced THP-1 macrophages. Int J Biol Sci. 2019;15(8):1571–1581. doi:10.7150/ijbs.34211.
- Richter J, Jimenez J, Nagatomo T, et al. Proton-pump inhibitor omeprazole attenuates hyperoxia induced lung injury. J Transl Med. 2016;14(1):247. doi:10.1186/s12967-016-1009-3.
- Busbee PB, Rouse M, Nagarkatti M, et al. Use of natural AhR ligands as potential therapeutic modalities against inflammatory disorders. Nutr Rev. 2013;71(6):353–369. doi:10.1111/nure.12024.
- Bessede A, Gargaro M, Pallotta MT, et al. Aryl hydrocarbon receptor control of a disease tolerance defence pathway. Nature. 2014;511(7508):184–190. doi:10.1038/nature13323.
- Meyer BK, Perdew GH. Characterization of the AhR-hsp90-XAP2 core complex and the role of the immunophilin-related protein XAP2 in AhR stabilization. Biochemistry. 1999;38(28):8907–8917. doi:10.1021/bi982223w.
- Furue M, Hashimoto-Hachiya A, Tsuji G. Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J Mol Sci. 2019;20(21):5424. doi:10.3390/ijms20215424.
- Kondraganti SR, Jiang W, Jaiswal AK, et al. Persistent induction of hepatic and pulmonary phase II enzymes by 3-methylcholanthrene in rats. Toxicol Sci. 2008;102(2):337–344. doi:10.1093/toxsci/kfn007.